Overview

Serotonergic Pharmacotherapy for Agitation of Dementia

Status:
Completed
Trial end date:
2002-04-01
Target enrollment:
Participant gender:
Summary
This study is a randomized, double-blind, placebo-controlled, fixed dose study currently being conducted on two geropsychiatric units at Western Psychiatric Institute and Clinic. It seeks to evaluate the short-term safety and efficacy of citalopram and perphenazine in the treatment of 112 patients suffering from behavioral disturbances associated with dementia. Findings from this research may directly lead to improved acute pharmacotherapy for psychosis and behavioral problems in patients diagnosed with dementia. Improved treatment of behavioral complications with reduced side effects would reduce excess disability in patients diagnosed with dementia, allowing them to be maintained in the community for greater periods of time.
Phase:
Phase 3
Details
Lead Sponsor:
Bruce Pollock
Collaborator:
National Institute of Mental Health (NIMH)
Treatments:
Citalopram
Perphenazine